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QUALITY OF LIFE (QOL) AND OTHER ENDPOINTS COMPARISON IN 
THE TREATMENT OF FACIAL LIPOATROPHY WITH INJECTION OF 
POLY-L-LACTIC ACID
Duracinsky M1, Dolivo M2, Beaulieu P3, Timsit J2, Secchi T4, Mouly F5, Lalanne B6, Leclerc P7, 
Chassany O8
1Centre Hospitalier Universitaire de Bicetre, Le Kremlin-Bicetre, France, 2Hop St Louis, paris, 
France, 3Dermatologue, Pontoise , France, 4Dermatologue, Lyon, France, 5Dermatologue, 
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OBJECTIVES: Lipodystrophy (LD) impacts QoL of HIV patients. Facial lipoatrophy 
(FL) is particularly stigmatizing. Patient Reported Outcomes measures (PROs) are not 
often used as a primary endpoint to measure interventions speciﬁc to LD. The aim of 
this study was to evaluate the QoL (primary endpoint) and other endpoints of HIV 
patients treated for FL by poly-L-lactic acid (PLLA) injection. METHODS: 245 
patients with FL were included in an open label prospective study and treated with 1 
to 5 treatment sessions at monthly intervals. Speciﬁc PROs were evaluated by the 
Assessment of Body Change and Distress (ABCD), including: QoL (21 items with 4 
domains, 0–100 scale), signs of LD (6 items, 0–6 point scale), and global satisfaction 
(1 item, 1–5 point scale) at baseline and 2 months after the last injection. The Overall 
Treatment Effect (OTE) (scale from 7 to  7) was also assessed at this date. Photo-
graphs were evaluated, blind by experts using James’ grading (1–4, 4 being severe FL). 
RESULTS: 191 patients completed the questionnaires. Mean age was 48 o 8 years, 
87% men, with FL since 5 o 3 years. The mean number of treatment sessions was 4 
o 1.3. The QoL global score improved signiﬁcantly by 13,5 points (24 %, p  0,001) 
and each of 4 domains improved: Satisfaction with the appearance 14,7 points; Psy-
chosocial impact 15,4; Fear of Future 10,5 and Relation with HAART 4,1. Global 
satisfaction improved from 2,6 to 3,3. Score of LD signs improved from 3,3 to 2,2. 
The OTE improved by 5,3 o 1.5 points. Photographs’ grading improved by 1.2 o 0.7 
points. All results were signiﬁcant (p  0,001). QoL score and Photo’s grading were 
not signiﬁcantly associated. CONCLUSIONS: QoL for people with FL improved sig-
niﬁcantly after PLLA injection. However, a modest correlation between PRO’s and 
photographs suggest that PRO’s are important endpoints in LD management 
interventions.
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TRANSLATION OF THE HIV PATIENT SYMPTOMS PROFILE INTO 5 
LANGUAGES SPOKEN IN ISRAEL
Brunel V, Salmassi L
MAPI Institute, Lyon, France
OBJECTIVES: Prior to use in an international clinical trial in 15 countries involving 
individuals suffering from HIV, the 87-item HIV PATIENT SYMPTOMS PROFILE 
(HPSP), underwent linguistic validation in 21 languages to ensure conceptual equiva-
lence, cultural relevance and harmonisation across languages. Special care had to be 
taken when producing the 5 translations for Israel (Arabic, Amharic, English, Hebrew    
and Russian) to adequately address the nuances associated with the diverging cultural           
heritage of these languages. METHODS: The following standardized methodology    
was employed: after a deﬁnition of the original concepts by the developer, the transla-
tion process was coordinated by a specialist for each target language involving the 
following steps: 1) two forward translations by professional translators, native speak-
ers of the target language and ﬂuent in English; 2) comparison and reconciliation of 
the translations; 3) backward translation by a native English speaker; 4) comparison 
of source and backward version; and (5) comprehension test on 6 HIV patients for 
each language. RESULTS: Linguistic and conceptual issues emerged during the trans-       
lation process in Israel, when addressing the issues outlined above. The most recurrent   
challenge was the absence of words in the target languages for speciﬁc concepts 
described in the English original. The translations had to resort to paraphrases and 
descriptions to provide the most appropriate approximation of the original notion 
in the target languages. Examples and their solutions will be described in the pre-
sentation. CONCLUSIONS: The 5 languages for Israel were produced according to         
a rigorous methodology to ensure conceptual equivalence, cultural relevance and 
harmonisation across countries whilst addressing the speciﬁc challenges of multiple 
languages spoken in one country. The rigorous methodology used to translate the 
HPSP will be necessary for the future psychometric analyses once international data 
are obtained for this instrument.
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CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLAND
Das R
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: Assessment of length of stay and patient ﬂow pathway of patients after 
admitted to Critical Care (Intensive Care Units [ICUs] or High-Dependency Units 
[HDUs]) with Pneumonia. METHODS: The analysis is based on inpatient hospital 
admission data from the National Health Service (NHS)’s Hospital Episode Statistics 
(HES) Database for England in 2005–2006. The study analysed patients admitted to 
an ICU with a primary or secondary diagnosis of Pneumonia. The bed days of and 
the destination of patients after the ﬁrst ICU stay (i.e. where the patients had not previ-
ously been admitted to Critical Care with Pneumonia in the same inpatient spell, based 
on the period from date of admission to date of discharge from hospital or death) 
formed the primary analysis. The same analysis for those patients moving to an HDU 
after their ﬁrst ICU stay was conducted. RESULTS: In 2005–2006, 838 ICU stays that 
met the criteria were identiﬁed. The average bed days for the ﬁrst ICU stay for patients 
with Pneumonia was 11.0 days (standard deviation [SD] 11.7 days). Of the patients 
in ICU with Pneumonia, 19.2% died. Of the remaining patients (where the destination 
data was recorded), 31.1% were moved to an HDU unit (same hospital), 67.7% 
moved to a non-critical ward (same hospital) and 1.2% were directly discharged from 
hospital. Of those patients that were moved into an HDU unit, the average bed days 
was 5.0 days (SD 5.7 days). At the end of their HDU stays, based on the destination 
data recorded, 75.9% were moved to a non-critical ward (same hospital), 21.7% were 
back to an ICU unit and 2.4% were discharged. Overall, the length of stay in hospital 
for patients with Pneumonia treated in critical care was, on average, 24.8 days 
(SD 23.2 days). CONCLUSIONS: At the end of the ﬁrst ICU stay with Pneumonia, 
19.2% died.
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LEAST COSTLY VACCINATION STRATEGY (WITH OR WITHOUT 
SCREENING FOR ANTOBODIES) FOR HEPATITIS A, HEPATITIS B, 
VARICELLA, MEASLES AND TETANUS IN CATALONIA, SPAIN
Plans–Rubió P1, Huang H2
1General Directorate of Public Health, Barcelona, Spain, 2Boston Health Economics, 
Waltham, MA, USA
OBJECTIVES: To determine the least costly immunization strategy, with or without 
screening for antibodies, against hepatitis A, hepatitis B, varicella, measles and tetanus 
in Catalonia, Spain. METHODS: The least costly immunization strategy for each 
vaccine in different age groups was determined using: 1) the prevalence of protected 
individuals (positive results), called p, observed in serological surveys in Catalonia and 
2) the critical prevalence of antibodies, called p*, that makes cost-effectiveness of 
vaccinating all individuals equal to screening and vaccination of susceptibles. Vacci-
nating all individuals was less costly than screening and vaccination when the preva-
lence of protected individuals was lower than p*. A formula to estimate p* was derived 
from the cost-effectiveness equations. RESULTS: The value of p* depended on screen-
ing and vaccination costs, programme compliance, screening test performance, vaccine 
efﬁcacy and disease costs. The following values of p* were obtained: 22.5 % for hepa-
titis A, 26.7 % for hepatitis B, 12.0 % for varicella, 100 % for measles and tetanus 
in adults, and 32.7 % for hepatitis A, 43.9 % for hepatitis B, 22.8 % for varicella, 
100 % for measles and tetanus in individuals aged 5–14 years. Based on these results 
and the prevalence of protected individuals observed in the population (p) in serologi-
cal surveys, the least costly immunization strategy was vaccination without screening 
for hepatitis B, measles and tetanus at all ages and for hepatitis A in adolescents, since 
p  p*, and screening and vaccination of susceptibles for varicella at all ages and 
for hepatitis A in adults, since p  p*. CONCLUSIONS: Immunization programmes 
should be developed taking into account the prevalence of protected individuals and 
the critical prevalence of antibodies to reduce costs.
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ECONOMIC IMPACT OF NEW MALARIA DIAGNOSTIC DEVICES ON 
THE MALARIA CONTROL PROGRAM IN BRAZIL
Quinn BP1, Hummel JM1, Laubscher M2, IJzerman MJ1
1University of Twente, Enschede, The Netherlands, 2Philips Research, Eindhoven, The 
Netherlands
OBJECTIVES: This study focuses on the health economical impact of new malaria 
diagnostic devices on the Malaria control processes in Brazil. Current diagnostic tools 
have disadvantages which prevent the total coverage of malaria risk regions. As a 
consequence, there is a high demand for diagnostic devices that can be used in remote 
settings. The objective of this research is to study the cost-effectiveness of new diag-
nostic devices. METHODS: Markov modeling and Monte Carlo simulation are used 
to compare the expected cost-effectiveness of the new devices Magneto-Optic Technol-
ogy (MOT), Rapid Diagnostic Tests (RDT), and Software Aided Microscopy (SAM), 
with the golden standard of microscopy. Outcome measures are the diagnostic and 
treatment costs as well as deaths avoided. Scenario analysis is used to compare differ-
ent implementation strategies of the devices that are expected to be or become most 
cost-effective. RESULTS: Microscopy has the highest cost-effectiveness ratio (1.78), 
followed by SAM (4.02). The access of Microscopy to remote risk regions is however 
limited. The implementation scenario with the highest health economic impact is to 
apply microscopy and to use in addition SAM in remote risk regions. At a total of 80 
per cent access to diagnosis, microscopy combined with SAM saves in Brazil up to 
36.000 lives (30 % improvement) with a cost-saving of 6 M (26 per cent savings). 
CONCLUSIONS: The outcomes provide clear guidelines for the investment in new 
devices. Accordingly, Markov modeling is a valuable tool for medical industry facing 
decisions concerning technology development and implementation.
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THE PREVALENCE, MORTALITY, AND COST OF CENTRAL LINE BLOOD 
STREAM INFECTIONS (CLABSI) IN US COMMUNITY HOSPITALS: 2002 
TO 2006
Dickson M, Stafkey-Mailey DR
University of South Carolina, Columbia, SC, USA
OBJECTIVES: The objective of this study was to estimate the national prevalence, 
mortality, and cost of CLABSIs. CLABSI prevalence in ICUs has been studied in a few 
hospitals, and some states mandate reporting selected blood stream infections (BSI), 
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but these laws are neither universal nor consistent. This study estimates the hospital-
wide prevalence, cost, and mortality of CLABSI-associated discharges for all US 
community hospitals. Hypotheses are that CLABSI prevalence and mortality are 
increasing and cost is unchanged. METHODS: Data for the study was extracted from 
the AHRQ HCUP National Inpatient Sample (NIS) database for 2002 and 2006. 
CLABSI was deﬁned as a discharge with an ICD9-CM procedure code for a central 
line procedure (38.92, 38.93, and 38.95) and an ICD9-CM diagnosis code for a 
BSI (24 codes). SAS Proc Surveyreg was used to estimate (log of) cost, and Surveylo-
gistic was used to estimate mortality and CLABSI prevalence. NIS weights were used 
to make national estimates, charges were adjusted using cost-to-charge ratios, and 
costs were adjusted to 2006 US dollars using the hospital service CPI. RESULTS: 
Average cost of a CLABSI-related hospitalization was $31,879 in 2006 dollars. Pres-
ence of CLABSI had a positive signiﬁcant effect on cost (0.128, p  0.001), as did the 
number of procedures (0.125, p  0.001) and LOS (0.034, p  0.001) while being 
female had a signiﬁcant negative effect (0.027, p  0.001). The time variable was not 
signiﬁcant (0.056, p  0.052). OR for CLABSI increased over time (1.196, p  0.001) 
when controlling for gender, LOS, number of procedures, liver disease, and renal 
failure. For mortality signiﬁcant ORs (p  0.001) were time (0.761), female (0.875), 
LOS (0.982), age (1.026), number of procedures (1.204), liver disease (1.814), 
and CLABSI (2.348). CONCLUSIONS: CLABSI-related hospital mortality in the 
US is decreasing as is the cost of treatment. However, the prevalence of CLABSI is 
increasing.
PIN77
THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY  
THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN 
PHYSICIANS’ CARE AND INSTITUTES, BUT NOT HOSPITAL 
OUTPATIENT CARE)
Wilbacher I, Endel G
Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria
OBJECTIVES: If a patient shows an infection, the physician has to decide which kind 
of anti-infective substance has to be prescribed. One method to ﬁgure this out is to 
order laboratory cultures. We want to ﬁnd out whether there is a correlation between 
the frequencies of cultures reimbursed and the number of prescriptions of anti-infective 
agents. METHODS: Claims data (2006) from physicians in free practice and institutes 
for laboratory medicine data for laboratory cultures were conducted out of different 
reimbursement catalogs in Austria. RESULTS: The rate of reimbursed cultures per 
prescription was 11% (for bacterial cultures and antibacterial medication J01, J04), 
63% (for mycotic cultures and antimycotic medication J02), 24% for viral cultures 
and antiviral medication J05) and 25% (for parasitic cultures and antiparasitical 
medication P01,02,03). If just those infections veriﬁed by cultures had caused a pre-
scription, the costs for anti-infective agents would have been 17% of the current 
number. If all prescriptions for anti-infective agents had been based on a culture, the 
prescription costs would have been 7,5 times higher. There are price differences for 
cultures due to various contract partners. If the lowest fee had been paid for each test 
we would have saved 33% of the current turnover for bacterial, 37% for mycotic, 
38% for viral, and 6% for parasitic infections. If the highest price had been paid we 
would have paid 75% (bacterial), 46% (mycotic), 164% (viral) and 33% (parasitic) 
more than the current turnover. CONCLUSIONS: Our further research will focus on 
the different categories of prescription for anti-infective agents, testing and also the 
guideline conformity of its use.
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DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER— 
A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME
Elbirt D1, Asher I1, Cohen Y1, Gradstein S1, Werner B1, Burke M1, Hammerman A2,  
Klang SH2, Sthoeger Z1
1Kaplan Medical Center, Rehovot, Israel, 2Clalit Health Services, Tel-Aviv, Israel
OBJECTIVES: To determine the cost effectiveness of direct monthly supply of 
HAART (Highly active anti retroviral therapy) medications at the AIDS center. 
METHODS: We analyzed 385 HIV patients, mostly (90%) immigrants from Africa 
(HIV subtype C) that were treated with HAART for more than one year prior to the 
initiation of the study. During the ﬁrst two years of the study, all patients received 
HAART prescriptions and the medications were supplied by local pharmacies. There-
after (next 2 years) all patients received their medications, monthly, by a nurse (on a 
part-time job basis) at our AIDS center. Compliance, immunological (CD4) and viro-
logical (VL) outcome between the two study periods (modes) were compared. 
RESULTS: The mean age of our patients, 48% males, at time of study initiation was 
35 o 13 (mean o SD) years. The mean time from HIV diagnosis was 7.3 o 4.1 years. 
Following the ﬁrst 2 years, 75% of the patients attended more then 90% of scheduled 
visits with 57% treatment adherence (90% of prescriptions). The mean CD4 count 
at the end of this period was 324.8 o 220.9 cell/mcl (66.7%  200 cells/mcl). Virologi-
cal failure (VL  40 copies/ml) was observed in 53% (mean VL 182,918 o 834,916 
copies/ml) of the treated patients. As a result of our intervention (two years of direct 
HAART supply), visits and treatment compliance increased, signiﬁcantly (p  0.001), 
to 90% and 84%, respectively. Concomitantly the CD4 cell counts increased to 470 
o 266 cell/mcl (p  0.24 compared to the ﬁrst study period) with 83.6% CD4 counts 
200 cells/mcl (p  0.001). A low rate of virological failures (28%; p  0.001; mean 
VL 15,068 o 73,382 copies/ml; p  0.001) was observed. CONCLUSIONS: Direct 
monthly supply of HAART medications at the HIV center is a very low cost mode 
which signiﬁcantly improves patient’s adherence as well as immunological and viro-
logical outcome.
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SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB 
IN HIGH-RISK PATIENTS
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OBJECTIVES: Palivizumab has been shown to reduce the number of respiratory syn-
cytial virus (VSR) related hospitalizations in preterm infants and patients with bron-
chopulmonary dysplasia or congestive heart disease. It is widely used but its high price 
raises concerns about its cost-effectiveness. The aim of this study was to systematically 
review economic evaluations (EE) of palivizumab in high-risk patients. METHODS: 
A comprehensive search for literature on the cost-effectiveness of palivizumab versus 
no prophylaxis was conducted. Bibliographic databases were searched from September 
2001 to February 2008. Additional relevant studies were identiﬁed from manual 
searches. Only studies published in English and Spanish were included. Quality was 
assessed using the Drummond criteria for EE. Two independent reviewers scrutinized 
retrieved references and assessed the quality of the studies. RESULTS: Twenty refer-
ences were included, representing a total of 32 EE: 20 cost-effectiveness analyses 
(CEA), 10 cost-utility analyses (CUA) and 2 cost-beneﬁt analyses (CBA). Quality was 
variable. Populations varied widely with some studies including all high-risk patients 
and others focusing on speciﬁc subgroups. Results were reported as incremental cost-
effectiveness ratios in terms of cost per hospitalization prevented, life-year gained or 
quality-adjusted life-year in all CEA and ACU and as cost-beneﬁt ratios in CBA. Esti-
mates of incremental ratios ranged from cost savings to incremental costs of a high 
order of magnitude. Assumptions on hospitalization rates in intensive care units, 
mortality and long-term consequences due to RSV infections, as well as acquisition 
cost of palivizumab seem to be related with more favourable ratios. A tendency for 
better results was also observed in studies receiving ﬁnancial support from the manu-
facturer. CONCLUSIONS: A true determination of cost-effectiveness of palivizumab 
is difﬁcult. However, costs of palivizumab seem to exceed potential cost-saving from 
reduced admission rates and might only prove to be cost-effective in a small subset of 
very high risk patients.
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THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH 
TECHNOLOGY ASSESSMENT (HTA) OF VACCINES—LESSONS 
LEARNED FROM FINLAND
Laine J1, Soini EJ2, Martikainen JA3
1Wyeth, Vantaa, Finland, 2ESiOR Oy, Kuopio, Finland, 3University of Kuopio, Kuopio, Finland
OBJECTIVES: The aim of economic evaluation (EE) is to provide information to help            
decision makers maximize health beneﬁts with given resources or advise how to attain 
given health targets efﬁciently in society. We examined the role and weight of EE in 
the HTA of vaccines in Finland and explored how EEs have and should have been 
conducted. METHODS: The methods and perspective of national EEs related to         
rotavirus and pneumococcal conjugate vaccination programs were evaluated. An 
ofﬁcial call for a rotavirus vaccination tender, competitive bidding process and tender 
decision-making criteria were explored. RESULTS: EE can have a crucial role when       
a new vaccine is considered for inclusion in a national vaccination program, which is 
necessary before a tender call for bids can be given. However, for tenders the pre-
dominant decision-making criterion seemed to be cost per vaccine. EE seemed to be 
conducted using a pair-wise comparison instead of multiple comparisons (i.e. different 
vaccines for a certain disease are compared only to no vaccination strategy). Advanced 
methods to characterize uncertainty, such as cost-effectiveness acceptability frontiers 
and value-of-information analyses, have not been applied. Also, no speciﬁc cost-effec-
tiveness threshold for new vaccines has been set in Finland although international 
references and Finnish home dialysis and bypass surgery thresholds have been cited 
in the evaluation reports. However, the literature revealed that setting a threshold may 
be impossible. Thus, we present an ideal EE process that enables value-based threshold 
pricing for manufacturers and decisions that can lead to efﬁciency. CONCLUSIONS: 
There is a discrepancy between the scientiﬁc principles and objectives of EE and real 
life in terms of national EEs of vaccines and tender calls in Finland. The current 
practice does not necessarily lead to optimal decisions based on cost-effectiveness. 
Particularly, multiple comparisons with valid prices should be encouraged.
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MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF 
PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING 
CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS
Endel G1, Schiller—Frühwirth I1, Urach C2, Popper N2, Zauner G2
1Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, 
2DWH—Simulation Services, Vienna, Vienna, Austria
OBJECTIVES: The aim of the current work is to implement a Markovian-model and 
a Differential Equation Model for simulating the pneumococcal illnesses and estimate 
the possibility of preventing the disease by vaccination of infants with the 7-valent 
serum. Implementing the two models opens the possibility of comparison of both and 
offers better insights on the inﬂuence of non linear effects like herd immunity and 
serotype replacement. METHODS: To assess the epidemiological inﬂuence of pneu-
mococcal infant vaccination using PCV7 in Austria a static Markovian-model and 
ordinary differential equation (ODE) modeling and simulation techniques are used. 
The Markovian model approach was classiﬁed as state of the art using a systematic 
literature review. (334 abstracts, 45 papers in detail) Implementing a model for serious 
diseases (meningitis, septicaemia and bacteraemic pneumonia) based on an infection 
